DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
KRN-330
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Cell surface A33 antigen binding agent
KRN-330
×
Maximum Phase:
1
First Approval:
None
UNII:
A64J777I28
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-1411
1
Antibody
Investigational
Unknown
Unknown
Lymphoma, Mantle-Cell
CD70 antigen cross-linking agent
MDX-1411
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CDP-484
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin-1 beta inhibitor
CDP-484
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZABENLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
EZABENLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7598
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-7598
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MASLIMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell receptor inhibitor
MASLIMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
E2.3
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders
Transferrin receptor inhibitor
E2.3
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IC14
2
Antibody
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Dengue; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome
Monocyte differentiation antigen CD14 inhibitor
IC14
×
Maximum Phase:
2
First Approval:
None
UNII:
23IQ3PO968
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KB003
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
KB003
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PATECLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
TNF-beta inhibitor
PATECLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
QOK1YYH7J2
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7160
2
Antibody
Investigational
Unknown
Unknown
Unknown
Epidermal growth factor receptor erbB1 antagonist
RG-7160
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROLEDUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Blood group Rh(D) polypeptide inhibitor
ROLEDUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Z4T52O86QV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZAGOTENEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Microtubule-associated protein tau inhibitor
ZAGOTENEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AY6V5E2GNX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANETUMAB RAVTANSINE
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Pancreatic Neoplasms
Mesothelin binding agent
ANETUMAB RAVTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
M170940PMI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SERIBANTUMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Pancreatic Neoplasms
Receptor tyrosine-protein kinase erbB-3 inhibitor
SERIBANTUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1N3L70MDFX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEZAMIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Amyloidosis
Serum amyloid P-component inhibitor
DEZAMIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6U3F28IT58
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUHMFG1
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
Mucin-1 other
HUHMFG1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IRATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Hematologic Neoplasms; Hodgkin Disease
Tumor necrosis factor receptor superfamily member 8 other
IRATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AYH22O1B1U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GANCOTAMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
DNA inhibitor
GANCOTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
S5Z216QNO6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZILTIVEKIMAB
2
Antibody
Investigational
Unknown
Unknown
Anemia; Renal Insufficiency, Chronic
Interleukin-6 binding agent
ZILTIVEKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AN3Y2B4SX4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
QUILIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal; Asthma; Urticaria
Ig epsilon chain C region inhibitor
QUILIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
26F96HRJ3W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORTICUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Oxidized LDL inhibitor
ORTICUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2O892R8U24
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TGN-1412
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Neoplasms; Psoriasis; Lupus Erythematosus, Systemic
T-cell-specific surface glycoprotein CD28 agonist
TGN-1412
×
Maximum Phase:
2
First Approval:
None
UNII:
POO0DOD3AS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONCOLYSIN B
2
Antibody
Investigational
Unknown
Unknown
Unknown
B-lymphocyte antigen CD19 binding agent
ONCOLYSIN B
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TILAVONEMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease; Supranuclear Palsy, Progressive
Microtubule-associated protein tau inhibitor
TILAVONEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
MY9Z7GDJ8J
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GEDIVUMAB
2
Antibody
Investigational
Unknown
Unknown
Influenza, Human
Hemagglutinin inhibitor
GEDIVUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6IRE1TI49I
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Major surface antigen inhibitor
TUVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
31Z0AB5WNC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INTETUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Prostatic Neoplasms
Integrin alpha-V/beta-3 antagonist
INTETUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
GQE1BJE2NI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PACMILIMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Breast Neoplasms; Melanoma
Programmed cell death 1 ligand 1 binding agent
PACMILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
ZXP96ZI2RA
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETOKIMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Dermatitis, Atopic; Peanut Hypersensitivity; Sinusitis
Interleukin-33 binding agent
ETOKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
7UWT6B0L2U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRO-542
2
Antibody
Investigational
Unknown
Unknown
HIV Infections; Acquired Immunodeficiency Syndrome
Envelope glycoprotein gp160 inhibitor
PRO-542
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
F16SIP 131I
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Tenascin binding agent
F16SIP 131I
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OPICINUMAB
2
Antibody
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Optic Neuritis
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
OPICINUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WX1WTN0Y15
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-522
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-522
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HBM9161
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
HBM9161
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
10
11
12
13
14
15
16
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA